Vystar Resumes Production of FDA Certified Rx3000 UV Light Air Purifiers for Use in Healthcare Facilities
- Rx3000 UV Light Air Purifier production shifts to Massachusetts to ensure quality, fast production & delivery
- Rx3000 inactivates on first pass 99.97% of harmful airborne viruses & bacteria.
- CDC states UV-C light is one of the most promising methods for Coronavirus (CoV-2) disinfection of face masks.
Worcester, MA, May 07, 2020 (GLOBE NEWSWIRE) -- Vystar Corp. (OTCQB: VYST) has shifted to Massachusetts production of its Rx3000, a hybrid ultraviolet (UV)-light air purification system designed specifically for hospitals. Rx3000 is FDA cleared as a Class II Medical Device and was designed by biomedical engineers for use in hospitals and healthcare facilities. Rx3000 utilizes ultraviolet-C (UV-C) germicidal irradiation (UVGI) to inactivate 99.97% of airborne viruses, bacteria and other pathogens on first pass.
“We are proud to say that we’ve resumed production of the RX3000 and it is now made in Worcester, Massachusetts, enabling more control over quality and distribution,” stated Steve Rotman, CEO of Vystar. “We are now producing 50 units per week. Once we finish testing these units, we plan to ramp up to 1500 units.”
The Rx3000 combines patented ViraTech germicidal UV-C light with a five-stage HEPA filtration proven in independent EPA- and FDA-certified laboratory testing to inactivate on first pass more than 99.97% of airborne viruses, bacteria and other contaminants. Rx3000 has been proven effective at inactivating airborne pathogens that cause pneumonia, influenza, MRSA (staph), streptococcus (whooping cough), tuberculosis (TB), measles and a myriad of other antibiotic-resistant and viral infections.
UV Light Treatment of Coronavirus (COVID-19) - The CDC has long stated that UVGI is effective in reducing the transmission of airborne bacterial and viral infections in hospitals, military housing, and classrooms. The CDC in April 2020 stated that UVGI is one of the most promising methods for decontamination of filtering facepiece respirators (FFR) for Coronavirus (SARS CoV-2), the virus that causes COVID-19. The report notes SARS CoV-2 may be inactivated by high doses of UV-C light, similar to the 99.9%-99.999% inactivation rate of UVGI on other viruses such as Influenza A (H1N1), Avian influenza A virus (H5N1), Influenza A (H7N9) A/Anhui/1/2013, Influenza A (H7N9) A/Shanghai/1/2013, MERS-CoV, and SARS-CoV. Rx3000 has not been tested directly for effectiveness against airborne Coronavirus (SARS CoV-2), however it uses the UVGI technology detailed in the CDC reports.